Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Doxorubicin; Epothilone B; Epothilones; Liposomal doxorubicin; Taxane

Criteria

Inclusion Criteria:

• 18 years of age or older

• Confirmed diagnosis of ovarian, fallopian or peritoneal cancer

• No more than three chemotherapy regimens

• Most recent regimen must have been platinum based

Exclusion Criteria:

• Have an unresolved bowel obstruction

• Have had previous chemotherapy within 3 weeks

• Recovering from any surgery for any cause

Other protocol-defined inclusion/exclusion criteria will apply.